COURTNEY LAPERRIERE: Open Payments
NPI 1558986281 · NORTHBOROUGH, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$741 in 30 payments from 12 companies in 2025. Trend: 2023 $204 · 2024 $262 · 2025 $741
Food & beverage: $741
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 9 | $178 |
| GENZYME CORPORATION | 4 | $126 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $91 |
| Grifols USA, LLC | 2 | $69 |
| GlaxoSmithKline, LLC. | 2 | $64 |
| Novartis Pharmaceuticals Corporation | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| CSL Behring | 1 | $34 |
| BioCryst US Sales Co., LLC | 1 | $29 |
| Verona Pharma, Inc. | 1 | $23 |
Products named: DUPIXENT, NEFFY, Prolastin-C Liquid, NUCALA, Andembry, XOLAIR, ORLADEYO, Ohtuvayre.
Industry payments across MA — which companies pay providers there.
